Short description
Ocumension Therapeutics is a pharmaceutical platform dedicated to identifying, developing, and commercializing ophthalmic therapies.
Description
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic therapies. The company’s vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since the inception, Ocumension Therapeutics has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. Ocumension Therapeutics believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Shanghai, Shanghai, China, Asia
Founded on
January 1, 2017
Exited on
July 10, 2020
Went public on
July 10, 2020
Stock symbol
1477
Non-profit?
No
Acquired?
No
Employees count
251-500
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccess, Blurry Noaccess
Sign in for full access
Funding rounds count
2
Portfolio organisations count
Nopepepe, Nopepepe
Sign in for full access
Lead investments count
2
Exits count
Noaccess, Absolutely Noaccess
Sign in for full access
IPO exits count
2